Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT.
We report a 54-year-old woman who received interferon alpha for haematological relapse of Ph-positive CML, 7 years after allogeneic BMT from an HLA-identical brother. Eighteen months after relapse, cytogenetic and molecular remission was achieved. She received interferon therapy for 25 months and it was discontinued when she developed skin lesions on her face and trunk, dysphagia and fever with respiratory failure and bilateral patchy airspace consolidation of the lung without microbiologic findings. Histologic features showed discoid lupus erythematosis, oesophagitis with pseudomembranes and a mixed pattern of lymphocytic bronchiolitis involving the alveoli and interstitial spaces all compatible with chronic GVHD. The patient was commenced on immunosuppressive therapy with complete clinical and radiological resolution. The available evidence supports an atypical presentation of chronic GVHD and suggests a role for interferon alpha in the pathogenesis of GVHD. To the best of our knowledge, this is the first case reported of severe chronic GVHD occurring during the course of interferon therapy for relapsed CML.
Serrano
J
J
Haematology Department, Fundación Jiménez Díaz, Madrid, Spain.
Prieto
E
E
Mazarbeitia
F
F
Román
A
A
Llamas
P
P
Tomás
J F
JF
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000633:toxicity; D016026:Bone Marrow Transplantation; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000139:chemically induced* / Q000209:etiology; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000633:toxicity*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008875:Middle Aged; D012008:Recurrence; D014184:Transplantation, Homologous
D000970:Antineoplastic Agents; D016898:Interferon-alpha